GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Realcan Pharmaceutical Group Co Ltd (SZSE:002589) » Definitions » 3-Year EPS without NRI Growth Rate

Realcan Pharmaceutical Group Co (SZSE:002589) 3-Year EPS without NRI Growth Rate

: 6.10% (As of Sep. 2023)
View and export this data going back to 2011. Start your Free Trial

Realcan Pharmaceutical Group Co's EPS without NRI for the three months ended in Sep. 2023 was ¥0.14.

During the past 12 months, Realcan Pharmaceutical Group Co's average EPS without NRI Growth Rate was -544.30% per year. During the past 3 years, the average EPS without NRI Growth Rate was 6.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Realcan Pharmaceutical Group Co was 54.00% per year. The lowest was -52.10% per year. And the median was 13.90% per year.


Competitive Comparison

For the Medical Distribution subindustry, Realcan Pharmaceutical Group Co's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Realcan Pharmaceutical Group Co 3-Year EPS without NRI Growth Rate Distribution

For the Medical Distribution industry and Healthcare sector, Realcan Pharmaceutical Group Co's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Realcan Pharmaceutical Group Co's 3-Year EPS without NRI Growth Rate falls into.



Realcan Pharmaceutical Group Co 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Realcan Pharmaceutical Group Co  (SZSE:002589) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Realcan Pharmaceutical Group Co 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Realcan Pharmaceutical Group Co's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Realcan Pharmaceutical Group Co (SZSE:002589) Business Description

Traded in Other Exchanges
N/A
Address
No. 326, Airport Road, Zhifu District, Shandong Province, Yantai, CHN, 264004
Realcan Pharmaceutical Group Co Ltd is a Chinese company engaged in direct pharmaceuticals distribution services. The company's main business is divided into the Drug, vaccine, medical device circulation service; Medical industry third-party logistics; Medical information service; Medical logistics service; Chinese medicine plate; Hospital management sector; Medical industry research and development production sector; and Medical industry financial sector.

Realcan Pharmaceutical Group Co (SZSE:002589) Headlines

No Headlines